Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy

AIMS: Obinutuzumab (G) is a humanized type II, Fc‐glycoengineered anti‐CD20 monoclonal antibody used in various indications, including patients with previously untreated front‐line follicular lymphoma. We investigated sources of variability in G exposure and association of progression‐free survival...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Main Authors: Jamois, Candice, Gibiansky, Ekaterina, Gibiansky, Leonid, Buchheit, Vincent, Sahin, Denis, Cartron, Guillaume, Marcus, Robert, Hiddemann, Wolfgang, Seymour, John F., Strefford, Jonathan C., Hargreaves, Chantal E., Meneses‐Lorente, Georgina, Frey, Nicolas, Fingerle‐Rowson, Günter
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595360/
https://ncbi.nlm.nih.gov/pubmed/30866056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13920
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares